Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression

BACKGROUND AND AIM:Crohn's disease (CD) is a heterogeneous disorder characterized by diverse clinical phenotypes. Childhood-onset CD has been described as a more aggressive phenotype. Genetic and immune factors may influence disease phenotype and clinical course. We examined the association of immune responses to microbial antigens with disease behavior and prospectively determined the influence of immune reactivity on disease progression in pediatric CD patients.METHODS:Sera were collected from 196 pediatric CD cases and tested for immune responses: anti-I2, anti-outer membrane protein C (anti-OmpC), anti-CBir1 flagellin (anti-CBir1), and anti-Saccharomyces-cerevisiae (ASCA) using ELISA. Associations between immune responses and clinical phenotype were evaluated.RESULTS:Fifty-eight patients (28%) developed internal penetrating and/or stricturing (IP/S) disease after a median follow-up of 18 months. Both anti-OmpC (p < 0.0006) and anti-I2 (p < 0.003) were associated with IP/S disease. The frequency of IP/S disease increased with increasing number of immune responses (p trend = 0.002). The odds of developing IP/S disease were highest in patients positive for all four immune responses (OR (95% CI): 11 (1.5–80.4); p= 0.03). Pediatric CD patients positive for ≥1 immune response progressed to IP/S disease sooner after diagnosis as compared to those negative for all immune responses (p < 0.03).CONCLUSIONS:The presence and magnitude of immune responses to microbial antigens are significantly associated with more aggressive disease phenotypes among children with CD. This is the first study to prospectively demonstrate that the time to develop a disease complication in children is significantly faster in the presence of immune reactivity, thereby predicting disease progression to more aggressive disease phenotypes among pediatric CD patients.

[1]  S. Targan,et al.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics , 2000, Gut.

[2]  J. Belaiche,et al.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.

[3]  K. Wilson,et al.  Differential Induction of Colitis and Gastritis in HLA-B27 Transgenic Rats Selectively Colonized with Bacteroides vulgatus or Escherichia coli , 1999, Infection and Immunity.

[4]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[5]  M. Dubinsky,et al.  Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[7]  W. Mow,et al.  Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. , 2004, Gastroenterology.

[8]  Jonathan Braun,et al.  Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. , 2002, Gastroenterology.

[9]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.

[10]  C. O'Morain,et al.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. , 2002, American journal of human genetics.

[11]  K. Wilson,et al.  Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. , 1999, Gastroenterology.

[12]  S. Targan,et al.  Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. , 2005, Gastroenterology.

[13]  H. Drummond,et al.  Sero-Reactivity to Microbial Components in Crohn's Disease Is Associated with Disease Severity and Progression, but not NOD2/CARD15 Genotype , 2004, The American Journal of Gastroenterology.

[14]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[15]  Alastair Forbes,et al.  The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. , 2002, Gastroenterology.

[16]  S. Targan,et al.  Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. , 2002, Gastroenterology.

[17]  Zhang Shuncai,et al.  Clinical Characteristics of Crohn's Disease , 2006 .

[18]  S. Targan,et al.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. , 1996, Gastroenterology.

[19]  T. Ahmad,et al.  The molecular classification of the clinical manifestations of Crohn's disease. , 2002, Gastroenterology.

[20]  A. Zinsmeister,et al.  Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. , 1998, Gastroenterology.

[21]  B. Childs,et al.  Crohn's disease: influence of age at diagnosis on site and clinical type of disease. , 1996, Gastroenterology.

[22]  J. Belaiche,et al.  Clinical characteristics of Crohn's disease in 72 families. , 1996, Gastroenterology.

[23]  U. Broeckel,et al.  CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  R. Sartor,et al.  Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. , 2005, Gastroenterology.